808 related articles for article (PubMed ID: 31013281)
1. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
2. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
[TBL] [Abstract][Full Text] [Related]
3. Survey of entity encounter experiences occasioned by inhaled
Davis AK; Clifton JM; Weaver EG; Hurwitz ES; Johnson MW; Griffiths RR
J Psychopharmacol; 2020 Sep; 34(9):1008-1020. PubMed ID: 32345112
[TBL] [Abstract][Full Text] [Related]
4. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
5. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
[TBL] [Abstract][Full Text] [Related]
6. Analysis of recreational psychedelic substance use experiences classified by substance.
Hase A; Erdmann M; Limbach V; Hasler G
Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
[TBL] [Abstract][Full Text] [Related]
7. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
Wilkes R; Roberts DM; Liknaitzky P; Brett J
Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
[TBL] [Abstract][Full Text] [Related]
8. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
9. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Griffiths R; Richards W; Johnson M; McCann U; Jesse R
J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
[TBL] [Abstract][Full Text] [Related]
10. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
[TBL] [Abstract][Full Text] [Related]
11. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Lea T; Amada N; Jungaberle H; Schecke H; Klein M
Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
[TBL] [Abstract][Full Text] [Related]
12. Psychedelic use and intimate partner violence: The role of emotion regulation.
Thiessen MS; Walsh Z; Bird BM; Lafrance A
J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
[TBL] [Abstract][Full Text] [Related]
13. Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications.
O'Callaghan C; Hubik DJ; Dwyer J; Williams M; Ross M
J Music Ther; 2020 Jul; 57(3):282-314. PubMed ID: 32227084
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
Hovmand OR; Poulsen ED; Arnfred S
J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
[TBL] [Abstract][Full Text] [Related]
15. The acute effects of classic psychedelics on memory in humans.
Healy CJ
Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
[TBL] [Abstract][Full Text] [Related]
16. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
[TBL] [Abstract][Full Text] [Related]
17. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
18. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.
Lawn W; Hallak JE; Crippa JA; Dos Santos R; Porffy L; Barratt MJ; Ferris JA; Winstock AR; Morgan CJA
Sci Rep; 2017 Nov; 7(1):15201. PubMed ID: 29123145
[TBL] [Abstract][Full Text] [Related]
19. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
[TBL] [Abstract][Full Text] [Related]
20. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
